SEC Form 4 · accession 0001209191-15-033568
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel G Welch
Director
Period of report
Apr 8, 2015
Accepted (ET)
Apr 10, 2015 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $59.95 | Apr 8, 2015 | A | 17,500 | A | — | Apr 7, 2025 | Common Stock | 17,500 | 17,500 | D |
Explanation of responses
- F1The option shall vest with respect to 1/36th of the shares monthly such that the options shall be fully vested on the third anniversary of the grant date.